🧬 Endocrinology Update: Mounjaro, Cell Therapy, Diabetes Tech & More
From cutting-edge cell therapy for Type 1 diabetes to AI platforms saving millions in Medicare, this week’s endocrinology update is packed with innovation. 🚀
📌 In This Episode: ✔️
Breakthrough T1D report calls for urgent cell therapy-based solutions
✔️ Mounjaro KwikPen launches across Canada with all six dose options
✔️ AI-powered PropheSee saves over $10 million in Medicare diabetes care
✔️ Glucotrack receives approval to begin long-term implantable CGM study in Australia
✔️ UW researchers identify brain neurons as a new target for Type 2 diabetes treatment
✔️ Sernova’s Cell Pouch helps two-thirds of trial patients achieve insulin independence
✔️ PolyNovo shares rise 10.5 percent after wound healing success in NovoSorb trial
✔️ Machine learning models predict GDM to T2D transition with high accuracy (AUC up to 0.92)
✔️ Only 43 percent of pregnancies meet thyroid screening guidelines; key risk factors often missed
✔️ PCOS found to raise hypertension risk by 40 percent, driven by insulin resistance
✔️ HELIOS trial shows AMX0035 improves symptoms in Wolfram Syndrome over 48 weeks
✔️ TransCon PTH Delivers Sustained Long-Term Benefits in Hypoparathyroidism
📢 Stay Ahead in Endocrinology Research!
✅ Like, share, and subscribe for weekly updates on diabetes, thyroid, hormone disorders, and rare endocrine conditions
✅ Visit www.lqventures.com for expert healthcare insights and consulting services